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Knowledge of the pattern of recurrence of surgically treated cases of adenocarcinoma of the oesophago-gastric junction is
important both for better understanding of their biological nature and for future strategic planning of therapy. The aim of this
study is to demonstrate and compare the pattern of dissemination and recurrence in patients with Type I and Type II
adenocarcinoma of oesophago-gastric junction. A prospective audit of the clinico-pathological features of patients who had
undergone surgery with curative intent for adenocarcinoma of oesophago-gastric junction between 1991 and 1996 was
undertaken. Patients were followed up by regular clinical examination. Clinical evaluation was supported by ultrasound,
computerised tomography, radio-isotope bone scan, endoscopy and laparotomy each with biopsy and histology where
appropriate. One hundred and sixty-nine patients with oesophago-gastric junction tumours (94 Type I and 75 Type II) have
been followed up for a median of 75.3 (57–133) months. One hundred and three patients developed proven recurrent
disease. The median time to recurrence was 23.3 (14.2–32.4) months for Type I and 20.5 (11.6–29.4) for Type II cancers.
The most frequent type of recurrence was haematogenous (56% of Type I recurrences and 54% of Type II) of which 56%
were detected within 1 year of surgery. The most frequent sites were to liver (27%), bone (18%) brain (11%) and lung (11%).
Local recurrence occurred in 33% of Type I cancer and 29% of Type II recurrences. Nodal recurrence occurred in 18 and
25% of Type I and Type II cancer recurrences, most frequently to coeliac or porta hepatis nodes (64%). Only 7% of Type I
and 15% of Type II cancer recurrences were by peritoneal dissemination. Type I and Type II adenocarcinoma of the
oesophago-gastric junction have a predominantly early, haematogenous pattern of recurrence. There is a need to better
identify the group of patients with small metastases at the time of diagnosis who are destined to develop recurrent disease in
order that they may be spared surgery and those with micro metastases in order that they can be offered multi-modality
therapy including early post operative or neo-adjuvant chemotherapy.
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Cancer registry and hospital data shows that there has been a
change in the topography of gastric cancer and topography and
morphology of oesophageal cancer with an increasing proportion
of cases of adenocarcinoma of the gastric cardia and lower oeso-
phagus i.e. adenocarcinoma of oesophago-gastric junction
(Antonioli and Goldman, 1982; Meyers et al, 1987; Hesketh et
al, 1989; Powell and McConkey, 1990; Blot et al, 1991; Pera et
al, 1993; McKinney et al, 1995). Similarities in terms of histo-
pathology and epidemiological trends have been identiﬁed
(Kalish et al, 1984; Wang et al, 1986; MacDonald and MacDo-
nald, 1987; Powell and McConkey, 1992; Heidl et al, 1993;
Siewert and Stein, 1998) and have led some observers to consider
the two cancers as one disease with similar aetiologies (Clark et
al, 1994).
A consensus conference of the International Gastric Cancer
Congress declared that cancers arising at or close to the oesopha-
go-gastric junction should be considered separately from gastric
and other oesophageal cancers and a new classiﬁcation system
for junctional cancers was devised (Table 1). According to this clas-
siﬁcation, Type I and II junctional cancers are becoming the
predominant oesophago-gastric cancer type. While the pattern of
recurrence following resection of oesophageal squamous cancer
and distal gastric cancer has been well documented (Gunderson
and Sosin, 1982; Law et al, 1996) the natural history of adenocar-
cinoma of the oesophago-gastric junction is yet to be deﬁned.
Accurate knowledge of the temporal, anatomical and biological
pattern of recurrence following surgery has important implications
for planning therapeutic strategies. The purpose of this study is to
analyse the pattern of recurrence in patients who have undergone
curative surgical resection for Type I and Type II adenocarcinoma
of the oesophago-gastric junction.
MATERIALS AND METHODS
A prospective audit was performed of all patients undergoing
surgery with curative intent for Type I and Type II adenocarcino-
ma of the oesophago-gastric junction. Between 1991 and 1996, 610
patients were referred and assessed. Of these 378 (62%) were
selected for surgery with the intention of curative resection. Over-
all, this group consisted of 195 patients with oesophageal cancer
and 183 patients with gastric cancer. Among these, there was a
total of 94 cases of adenocarcinoma of the lowest 5 cm of the oeso-
phagus (Type I junctional cancers) and 75 of the gastric cardia
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resection. All patients underwent detailed pre-operative assessment
prior to selection for surgery. This assessment included appraisal of
tumour stage and resectability by chest X-ray, endoscopy, abdom-
inal ultrasound scan and thoraco-abdominal spiral CT scan.
Tumour site was determined at endoscopy along with a record
of proximal and distal margins and the position of the oesophago-
gastric junction. Clinical and pathological details, based on a
standardised reporting protocol were recorded
The operative approach and extent of procedure performed for
tumours around the oesophago-gastric junction was tailored to
each case with respect to tumour stage and patient ﬁtness. Ninety
two patients with Type I junctional cancers underwent two stage
sub-total oesophagectomy with two ﬁeld lymphadenectomy (Grif-
ﬁn, 1998) and two underwent a thoraco-abdominal gastro-
oesophagectomy with D2 lymphadenectomy (Heitmiller, 1992).
Of the Type II junctional cancer patients, one underwent a two
stage oesophago-gastrectomy and 74 underwent a total gastrectomy
with Roux-en-Y oesophago-jejunal anastomosis: 18 had a D1 and
56 had D2 lymphadenectomy. Additionally seven patients had sple-
nectomy; two along with distal pancreatectomy. Strict adherence to
the Japanese Rules for Gastric Cancer Surgery recommended by the
Japanese Research Society for Gastric Cancer (JRSGC) was
observed for description of lymphadenectomy. Only if all N1 and
N2 Stations were resected en bloc with the stomach, was the resec-
tion deemed D2. For those who fell short of this, most commonly
for failure to remove splenic hilar nodes, D1 was used. In effect,
our ‘D1’ resections were invariably more extensive than simply
the N1 en bloc resection as described by the JRSGC. The approach
used was typically the thoraco-abdominal approach in the former
part of the series and latterly changed to a transhiatal approach
with an associated reduction in peri-operative complications
(Wayman et al, 1999). Neo-adjuvant or adjuvant therapy was not
used in any of this group of patients.
All patients underwent clinical review at 6 weeks following
discharge and 3 monthly thereafter. Clinical review consisted of
history and abdominal examination. No investigations were routi-
nely instituted as long as the patient remained symptomatically
well with no abnormality on clinical examination. A protocol for
investigation of symptomatic recurrence was developed. In this,
primary symptoms prompted investigation as shown in Table 2.
In addition, autopsy information was available in eight patients,
of whom six had recurrent disease. Post mortem examination
was not routinely requested in patients with recurrent disease
detected prior to death.
All data were compiled prospectively onto proformas and trans-
ferred onto a database (Paradox 3.1 for DOS). Disease free survival
was calculated by the method described by Kaplan–Meier with
univariate comparisons in median survival by the log rank test
and multivariate analyses by Cox Regression. Comparison of
continuous data between groups was by the Mann–Whitney U-test
and ordinal data by the w
2 test. Analyses were performed using the
Statistics Package for the Social Sciences (SPSS 6.1.3 for
Windows
1, Chicago, IL, USA).
RESULTS
One hundred and sixty-nine patients with tumours of the gastro-
oesophageal junction who underwent resection with curative intent
were followed and studied (Table 3). There was a higher male to
female ratio in patients with Type I junctional cancer. There was
a higher proportion of tumours conﬁned to the mucosa and
sub-mucosa in Type I cancers compared to Type II (26% vs 7%;
w
2=17.2, 4 df, P=0.002) and a higher proportion of lymph node
negative patients (38% vs 23%; w
2= 4.0, 1 df, P=0.04). There was
no signiﬁcant difference in the other histopathological parameters
measured. In the time period studied, the median yield of the
two-ﬁeld lymphadenectomy was 13 (4–33), with involvement of
median 4 (1–20), the D1 lymphadenectomy yielded a median of
21(4–53) nodes with a median positivity of 6 (1–43) while those
described as D2 resection yielded 21 (1–52) with a positivity of
yield of 5 (1–30).
Median follow up of patients was 75.3 months (range 57–133).
Of the 169 patients who underwent resection with curative intent,
103 patients developed recurrent disease; 55 out of 94 of Type I
and 48 out of 75 Type II junctional tumours. A further 19 patients
have died without evidence of recurrence including ﬁve within 30
days of surgery, and a further four within 3 months of surgery
(Table 4).
The median, recurrence free survival for Type I and Type II
junctional cancers was 699 (425–973) days vs 615 (348–882)
(w
2= 0.04, 1 df P=0.84) (Figure 1). The median time to death
following recurrence was 61 (0–782) days, but highly variable
and was similar for Type I (46 (0–445)) and Type II (62 (0–
782)) cancers. Time to death for each of the patterns of recur-
rence was not signiﬁcantly different; haematogenous (52 (0–
445)), lymphatic (143 (19–782)), local (63 (0–339)) and perito-
neal spread (38 (14–184)) days. Lymph node status, depth of
invasion, grade of differentiation and the presence of lymphatic,
peri-neural or vascular invasion and the presence of positive
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Table 1 Table of classiﬁcation of junctional cancer types (from Siewert
and Stein, 1998)
Junctional cancer Description
Type I Adenocarcinoma of the distal oesophagus arising in an area of
specialised intestinal metaplasia and which may inﬁltrate the
oesophago-gastric junction.
Type II True carcinoma of the cardia arising from the cardiac
epithelium or short segments with intestinal metaplasia at
the oesophagogastric junction; this entitiy is also often
referred to as ‘junctional carcinoma’.
Type III Sub-cardial gastric carcinoma which inﬁltrates the oesophago-
gastric junction and distal oesophagus from below.
Table 2 Table of investigations performed in response to symptoms suggestive of recurrence
Symptom/clinical signs Primary investigation Secondary investigation
a
Hoarse voice Direct laryngoscopy, Endoscopy
b Spiral CT of thorax
Dysphagia Endoscopy and biopsy
b Spiral CT of thorax
Abdominal pain or weight loss LFT’s, Abdominal USS, Endoscopy
b Spiral CT of abdomen and thorax
Skeletal pain X-ray, Bone scan
Headache/behavioural change CT head
Lethargy/breathlessness Blood count, CXR Spiral CT of abdomen and thorax
Intestinal obstruction Abdominal X-ray Laparotomy
b
aPerformed if primary investigation fails to exclude recurrences or symptoms persist despite normal examina-
tion.
bHistological diagnosis also obtained.
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survival on univariate analysis (Table 5). On multivariate analysis
of disease free survival only lymph node status and histological
evidence of lymphatic invasion were signiﬁcant independent
prognostic factors (Table 5, Figure 2). Extent of lymphadenect-
omy in the group of patients undergoing total gastrectomy
(‘D1’ vs ‘D2’) was not signiﬁcantly related to timing or pattern
of recurrence. Sub-analysis of the lymph node positive group
revealed nodal burden (where high burden was regarded as four
or more positive) was a signiﬁcant prognostic factor (Figure 3)
(P=0.0004).
The distribution of recurrent disease was similar in Type I
and Type II junctional cancers (Table 6). The commonest type
of recurrence in both was haematogenous, occurring in 56% of
Type I and 54% of Type II junctional cancer recurrences.
Within the group of patients with haematogenous recurrence
the most frequent metastatic sites were bone and hepatic
(Table 7). Local recurrence occurred in 32 patients (33% of
Type I recurrence cases, 29% of Type II recurrence cases) at
the tumour bed including the mediastinum and oesophago-jeju-
nal or oesophago-gastric anastomosis. In a further 22 cases,
local lymph node groups could be distinguished on USS
(n=7) or spiral CT scan (n=15). The most common lymph
node groups involved were are listed below (Table 8). In addi-
tion, pulmonary lymphangitis carcinomatosis was a feature of
recurrence in four patients. Distant peritoneal disease was diag-
nosed in 7% of Type I and 14.5% of Type II junctional cancer
recurrences by a laparotomy (n=3), spiral CT scan (n=6) or
autopsy (n=2).
Eleven patients (15%) had positive resection margins of
which six cases had tumour within the anastomotic donuts.
The presence of positive resection margins was associated with
poorer disease free survival although this was dependent on
lymph node status (Table 5). The site of recurrence in these
patients was local in only four, haematogenous in seven (one
case having both lymph node and haematogenous recurrence),
peritoneal in two and lymphatic in one. Similarly, the presence
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(Log rank test = 57.66, 1 df; P<0.00001)
Figure 2 Kaplan–Meier plot of recurrence free survival of cases of
Lymph node positive (broken line) and negative (straight line) junctional
cancers.
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Figure 1 Kaplan–Meier plot of recurrence free survival of cases of Type
I (broken line) and Type II (straight line) junctional cancers.
Table 4 Comparison of outcome of patients with Type I and Type II
junctional cancers
Type I Type II
(n=94) (n=75)
Alive 33 18
Deaths (recurrence) 55 48
Deaths (recurrence free) 6 9
Peri-operative deaths 3 2
MI 1 1
CVA 1 3
Brochogenic ca. – 1
Small cell lung ca. – 1
Monocytoid leukaemia – 1
Rectal ca. 1 –
Table 3 Comparison of demographic and histopathological parameters
in patients with Type I and Type II junctional cancers
Type I Type II
(n=94) (n=75) Signiﬁcance
Age (range) 64(40–77) 70(41–78) ns
Male:female 6.9:1 2.9:1 P=0.04
Differentiation (%)
Well 19.6 14.5
Moderate 32.6 32.7 ns
Poor 46.7 48.3
Lymphatic invasion (%) 26.6 40.0 ns
Perineural invasion (%) 40.4 42.3 ns
Vascular invasion (%) 18.1 25.9 ns
Stage (%)
Tis/T1 26 7
T2 16 40
T3 55 51
T4 2 1 P=0.002
LN7ve 38 23
LN+ve 62 77 P=0.04
Table 5 Signiﬁcance of prognostic factors for disease free survival of
Type I and Type II oesophago-gastric junctional cancer patients
Univariate Multivariate
w
2 analysis analysis
Lymph node +ve 51.551407 50.0001 50.001
Lymphatic invasion 42.28079 50.0001 50.05
Anastomotic donuts +ve 9.458205 50.001 ns
Positive longitudinal resection margins 6.981626 50.05 ns
Depth of invasion (T stage) 30.470782 50.0001 ns
Tumour grade 16.481826 50.005 ns
Peri-neural invasion 32.53679 50.0001 ns
Vascular invasion 23.787728 50.0001 ns
Adenocarcinoma of the OG junction
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1223–1229of positive lymph nodes in the resected specimen was associated
with haematogenous recurrence (n=45) more than lymphatic
(n=16), local (n=20), and peritoneal (n=11) recurrence.
Haematogenous recurrence in particular tended to occur
rapidly after surgery; median time to recurrence haematogenous
(360 (10–1844)), lymphatic (547 (181–1162)), local (364
(146–1685)) and peritoneal spread (149 (132–1091)) days
(Figure 4). Patients in whom recurrent disease was detectable
within the ﬁrst year were considered separately since they argu-
ably represent a group of outright treatment failures. This group
of patients (n=50) showed a predominance of haematogenous
recurrence (46%). Fifty-six per cent of haematogenous recurrence
(30 out of 57) occurred within 12 months. Lymph node involve-
ment was the only signiﬁcant prognostic marker for ﬁrst year
recurrence of any site compared with later recurrence
(P40.0001) and within this group 77% had had a high nodal
burden.
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Figure 3 Kaplan–Meier plot of recurrence free survival of cases of
Lymph node positive junctional cancers with low (54 nodes positive)
(straight line) and high nodal burden (broken line).
Table 6 Table of number of patients with recurrence at each site; Type I
vs Type II junctional cancer
Type I (n=55) Type II (n=48)
Haematogenous 30 26
Local 18 14
Lymph node 10 12
Peritoneal 4 7
The sites of recurrence were grouped as Local, when the recurrence occurred at the
tumour bed, anastomosis or oesophageal or gastric remnant, Peritoneal when the
recurrence was on the visceral or parietal peritoneal surface away from the site of
the primary cancer, Lymph node when recurrence was within deﬁnable local lymph
node groups and Haematogenous when recurrence recurred at a site distant to the
original tumour in which blood borne dissemination was indicated.
Table 7 Table of frequency of diagnosis of haematogenous recurrence
(Type I and II junctional cancers)
Site Type I (n=30) Type II (n=26)
Liver 6 9
Bone 7 3
Brain 2 4
Lung 4 2
Skin 1 3
Adrenal 1 1
Table 8 Table of frequency of diagnosis of Lymphatic recurrences (Type
I and II junctional cancers)
Site Type I (n=10) Type II (n=12)
Coeliac axis 4 3
Porta 3 4
Retrocrural/aortocaval 1 3
Supraclavicular 3 0
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Figure 4 Bar charts illustrating timing of each mode of recurrence. Time
in months on x axis. Number of cases with recurrence on y axis.
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Natural and surgically manipulated pathways of tumour spread
determine subsequent patterns of recurrence. In oesophago-gastric
cancer direct extension can lead to local recurrence, lymphatogen-
ous spread to local lymph recurrence, haematogenous spread to
recurrence at distant sites and transcoelomic spread to peritoneal
recurrence. The results of this study suggest that Type I and Type
II junctional cancers have a similar pattern of dissemination and
recurrence which is different from that reported for distal gastric
cancer and oesophageal squamous carcinoma.
Caution must be applied when comparing these ﬁndings with
previously reported work. The criteria used for detecting and diag-
nosing recurrence in this clinically based study are inferior to
studies based on a systematic planned ‘Second look’ laparotomy,
symptomatic re-look laparotomy or autopsy. Only 6% of recur-
rences in this series were diagnosed by post mortem
examination. This study is therefore biased towards diagnosing
symptomatic recurrence and that which can be most easily imaged.
It may particularly underestimate the incidence of small peritoneal
and local recurrences.
The categorisation in this study into local, lymphatic, peritoneal
and haematogenous recurrence is somewhat artiﬁcial. There is
clearly likely to be considerable overlap between local and lympha-
tic recurrence due to the difﬁculty in distinguishing lymph node
groups on CT scan. Also, some cases of local recurrence may repre-
sent locally conﬁned peritoneal dissemination or a feature of more
widespread peritoneal dissemination too subtle to be detected by
CT and USS, both of which are known to be inaccurate in diagnos-
ing peritoneal dissemination. Nevertheless, haematogenous
dissemination is, in this study, more objectively deﬁned.
The earliest evidence for the pattern of failure following gastric
resections for cancer comes from autopsy studies. McNeer found
that of 92 patients undergoing ‘curative sub-total gastrectomy’
80.4% were found to have evidence of recurrence at post-mortem
(McNeer et al, 1951). Among these the great majority were local
recurrences; 65.2% had recurrence in the gastric remnant, gastroen-
terostomy or duodenum while 52.2% had recurrence in peri-gastric
nodes and stomach bed, 30% had peritoneal seedlings and 40%
had haematogenous recurrence. Such post mortem data lacks any
information about timing of recurrence.
Wangensteen, with his policy of systematic planned re-opera-
tions following ‘curative’ operations was the ﬁrst to be able to
map the incidence and precise areas of failure of gastric cancer
resections before they became clinically apparent (Wangensteen et
al, 1954). Although such a policy proved to be of little therapeutic
value, this and a subsequent similar analysis by Gunderson and
Sosin (1982) provided invaluable information and moulded
opinion about the nature and pattern of gastric cancer recurrence.
In their work, they found that 87.8% of failures were in some part
contributed to by local and/or regional recurrence deﬁned as recur-
rence in local lymph node groups or tumour bed; 53.7% had
peritoneal seedlings, 29.3% of which were diffuse. Of 105 patients
followed up, only ﬁve had isolated distant metastases. At the time
of this work, there was a general acceptance that the majority of
patients with gastric cancer would die with locally recurrent disease
and the purpose of such studies was to deﬁne the anatomy of this
recurrence with a view to planning adjuvant radiotherapy sche-
dules. More recent data for the pattern of failure of gastric
cancer comes from Japan and Korea. There the disease is still
predominantly of the distal stomach. In these series peritoneal
recurrence remains the predominant cause of failure (Maehara et
al, 2000; Yoo et al, 2000). Our results suggest that adenocarcinoma
of the oesophago-gastric junction has a different natural history
which should prompt a re-evaluation of adjuvant and neo-adjuvant
therapies.
The pattern of recurrence of oesophageal cancer has been
studied but has previously concentrated on squamous cell carcino-
ma (Law et al, 1996). Data from Hong Kong on 108 patients
undergoing oesophagectomy and two-ﬁeld lymphadenectomy with
curative intent demonstrated recurrence in 56. Two thirds of
patients with recurrence presented within the ﬁrst year. The
authors categorised recurrence as primarily intra- (equivalent to
local recurrence in our study) or extra-thoracic. The majority of
recurrences were extra-thoracic (44 vs 33 out of 56). Of the extra-
thoracic recurrences, 28 were by haematogenous dissemination to
distant organs and 17 to lymph nodes; speciﬁcally cervical
(n=12) and abdominal (n=5). The incidence of identiﬁed local
recurrence (25%) is much greater than in our study for adenocar-
cinoma of the lower oesophagus (9%) or oesophago-gastric
junction (15%). This may be partly to do with a higher proportion
of early cancers in our Type I group. However, even as a propor-
tion of those patients with recurrence, local recurrence is more
common for squamous cancer (48%) than our ﬁnding with adeno-
carcinoma of the lower oesophagus (27%) or the gastric cardia
(38%).
There may be many reasons for differences between the ﬁndings
of this study compared to historical observations. The more radical
nature of the surgery performed with perhaps greater attention to
lymphadenectomy may account for the improved local disease
control. The radical two-ﬁeld lymphadenectomy appears to give
good local disease control (Dresner and Grifﬁn, 2001) and the total
gastrectomy with D1 or D2 lymphadenectomy practised for the
junctional cancers may also confer better local disease control than
the more traditional distal and subtotal gastric resections. There are
some conﬂicting reports suggesting that lymphadenectomy confers
no survival beneﬁt (Hulscher et al, 2001) however such studies are
either too small with insufﬁcient statistical power, not stratiﬁed by
tumour stage or lack standardisation of technique. The choice of
operation and extent of lymphadenectomy may have some inﬂu-
ence on the pattern of recurrence. The majority of Type II
cancers underwent total gastrectomy with abdominal lymphade-
nectomy and yet there are some who would suggest that
mediastinal lymphadenectomy is appropriate in such cases. Our
series did not have any examples of mediastinal recurrence. The
other problem with total gastrectomy is the difﬁculty with proxi-
mal tumour clearance. In our series, following total gastrectomy,
incomplete resection margin occurred in 15% of cases. In such
cases, it may have been preferable to perform sub-total gastro-
oesophagectomy. However this would compromise the abdominal
lymphadenectomy. Interestingly, the pattern of recurrence in such
patients was that which one would anticipate from the lymph node
status. All had heavy nodal burden and resection was ultimately
palliative with early systemic, not local recurrence. One might
argue that for such patients, destined to have early recurrence,
sparing them thoracotomy may have ultimately been to their bene-
ﬁt rather than their detriment.
It may also be that lymphadenectomy, if it does not confer
survival beneﬁt, may still alter the pattern of recurrence and be
the explanation for the relatively lower incidence of local recur-
rence compared with historical data. The high incidence of early,
haematogenous recurrence suggests genuine biological differences
between the now predominating adenocarcinoma of the oesopha-
go-gastric junction and the previously described squamous
carcinoma of the oesophagus and mainly distal gastric cancers. It
is somewhat difﬁcult to draw contemporary comparisons as the
incidence of more distal gastric cancer has fallen signiﬁcantly in
the West in the last two decades. Data from Japan, where radical
lymphadenectomy has been common place for longer, would
suggest that the predominant site of recurrence in distal gastric
cancers remains local despite lymphadenectomy.
There was a signiﬁcant difference in the stage at diagnosis of
Type I and Type II junctional cancers in this study. The relatively
higher incidence of lymph node negative and T1 cancers in the
Type I group may be explained by their earlier presentation
through Barrett’s surveillance programmes at this unit and other
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1223–1229tertiary referrals. Otherwise the similarity in their natural history,
age distribution and histological characteristics suggest that Type
I and Type II junctional cancers are biologically similar tumours.
Other groups have identiﬁed pathological and demographic simila-
rities between these cancers which contrast with differences
between cardia and more distal stomach cancers (Kalish et al,
1984; Wang et al, 1986; MacDonald and MacDonald, 1987). Inter-
estingly, our results do suggest differences with respect to the sex
ratio. This may be explained by contamination of the Type II junc-
tional group with Type III proximal third gastric cancers inherent
in the retrospective reclassiﬁcation of tumour type.
During our study period, the system of classiﬁcation according
to the IGCA was not available. Our study reclassiﬁes, in retrospect,
tumours previously classiﬁed according to ICD 9 codes as adeno-
carcinoma of the lower oesophagus (ICD 1505) and
adenocarcinoma of the oesophagogastric junction/gastric cardia
(ICD 1510). There is a risk of confusion in the data by such reclas-
siﬁcation. Indeed this may also be a consideration of prospective
classiﬁcation. In our series we have two levels of control to mini-
mise such cross-classiﬁcation. The ﬁrst is that in addition to site
codes, according to the standardised staging protocol used,
measurements were made at the time of endoscopy which can be
used to accurately classify tumour position. The position of the
diaphragm and whether the tumour was visible at the hiatus on
retroﬂexion of the endoscope were also recorded. In addition,
accurate position of the tumour was conﬁrmed by the pathologist
who also followed a standardised protocol for dissection and
reporting of cases.
The early, haematogenous pattern of recurrence identiﬁed in this
study for adenocarcinoma of the oesophago-gastric junction has
important clinical implications. There are two groups of patients
whom we must try to identify. There are those who already have
metastatic disease at the time of diagnosis but who are not being
identiﬁed by current routine staging techniques and those who
have micrometastases. The former group are unlikely to be cured
and may die early without beneﬁting from radical treatment. In
such cases consideration should be given to non-operative treat-
ment. For the latter group if they are elderly or unﬁt, non-
operative treatment may be considered while for those in whom
surgery is appropriate, treatment strategies designed to combat
the early systemic recurrence should be considered. In such
patients, inclusion in trials of systemic, neo-adjuvant therapy
should be considered. Undoubtedly, chemotherapy will have an
important role in any such therapeutic regime in order to control
the early, haematogenous phase of recurrent disease.
Staging protocols should be reviewed. We are currently piloting,
with encouraging results, a policy of radio-isotope bone scans
before undertaking radical treatment. O’Sullivan et al (1999) have
demonstrated that micrometastases are detectable in bone marrow
in as many as 88% of cases of even early disease. There is no
evidence that these ﬁndings correlate with subsequent haematogen-
ous recurrence nor that their prognostic signiﬁcance is independent
of lymph node status. For these reasons, we do not use the techni-
que in clinical practice. The presence of lymph node spread at the
time of surgery was the strongest and only independent predictor
of recurrence and speciﬁcally early haematogenous recurrence in
our series. Our results have shown that pathologically assessed high
lymph node burden is associated with the highest incidence of early
haematogenous recurrence. Identiﬁcation of high nodal burden
pre-operatively may be a means of identifying those patients with
micrometastases at risk of early recurrence. We now pay close
attention to nodal burden as assessed pre-operatively by endo-
scopic ultrasound scan and CT.
In conclusion, the pattern of recurrence of Type I and Type II
adenocarcinoma of the oesophagogastric junction is similar and
characterised by early systemic recurrence especially in patients
with lymph node disease at the time of surgery. Further research
is required to better identify those with metastatic disease at the
time of diagnosis who will not beneﬁt from surgery and those most
likely to have micrometastatic disease who may beneﬁt from
systemic neo-adjuvant chemotherapy as part of the multimodality
treatment of this cancer.
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